Sarah Kathryn Rouan - 31 Mar 2025 Form 4/A - Amendment Insider Report for Viking Therapeutics, Inc. (VKTX)

Role: Director
Signature: /s/ Michael Morneau, as Attorney-in-Fact
Issuer symbol: VKTX
Transactions as of: 31 Mar 2025
Net transactions value: +$29,943
Form type: 4/A - Amendment
Filing time: 08 Apr 2025, 19:05:30 UTC
Date Of Original Report: 02 Apr 2025
Previous filing: 06 Jan 2025
Next filing: 05 Jan 2026
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VKTX	Common Stock, par value $0.00001 per share	Purchase	$29,943	+1,240		$24.15	1,240	31 Mar 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person's purchase of shares of the Issuer's common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 1,240 shares, with the Reporting Person's sale of shares of the Issuer's common stock at a price of $80.89 per share on October 25, 2024. The Reporting Person has, on a voluntary basis, made arrangements with the Issuer to pay $70,316.25 to the Issuer, representing the full amount of the profit realized in connection with the short-swing transaction, less transactions costs.

Content

The Reporting Person's purchase of shares of the Issuer's common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 1,240 shares, with the Reporting Person's sale of shares of the Issuer's common stock at a price of $80.89 per share on October 25, 2024. The Reporting Person has, on a voluntary basis, made arrangements with the Issuer to pay $70,316.25 to the Issuer, representing the full amount of the profit realized in connection with the short-swing transaction, less transactions costs.

Remarks:

This Form 4 is being amended solely to add new footnote 1 regarding the Reporting Person's agreement to pay the profit realized to the Issuer.